Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trial. Lancet Oncol. 2023 Mar; 24(3):273-285.
View in:
PubMed
Escalation, De-escalation, Adaptation, Speciation, Customization: The New Approaches to Breast Cancer. Hematol Oncol Clin North Am. 2023 02; 37(1):xiii-xvi.
View in:
PubMed
Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials. J Clin Oncol. 2023 Mar 01; 41(7):1376-1382.
View in:
PubMed
Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT. J Clin Oncol. 2023 Mar 01; 41(7):1370-1375.
View in:
PubMed
ASO Visual Abstract: Expanding Staging Criteria in T1-2N0 Hormone Receptor-Positive Breast Cancer Patients Enrolled in TAILORx. Ann Surg Oncol. 2022 12; 29(13):8024-8025.
View in:
PubMed
Treatment discontinuation, patient-reported toxicities and quality-of-life by age following trastuzumab emtansine or paclitaxel/trastuzumab (ATEMPT). NPJ Breast Cancer. 2022 Nov 30; 8(1):127.
View in:
PubMed
ASO Visual Abstract: Sentinel Lymph Node Biopsy Alone is Adequate for Chemotherapy Decisions in Postmenopausal Early-Stage, Hormone-Receptor-Positive, HER2-Negative Breast Cancer with 1-3 Positive Sentinel Lymph Nodes. Ann Surg Oncol. 2022 11; 29(12):7683-7684.
View in:
PubMed
'ADVANCE' (a pilot trial) ADjuVANt chemotherapy in the elderly: Developing and evaluating lower-toxicity chemotherapy options for older patients with breast cancer. J Geriatr Oncol. 2023 Jan; 14(1):101377.
View in:
PubMed
Postneoadjuvant treatment for triple-negative breast cancer. Curr Opin Oncol. 2022 11 01; 34(6):623-634.
View in:
PubMed
Expanding the Staging Criteria for T1-2N0 Hormone-Receptor Positive Breast Cancer Patients Enrolled in TAILORx. Ann Surg Oncol. 2022 Dec; 29(13):8016-8023.
View in:
PubMed
Sentinel Lymph Node Biopsy Alone is Adequate for Chemotherapy Decisions in Postmenopausal Early-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer with One to Three Positive Sentinel Lymph Nodes. Ann Surg Oncol. 2022 Nov; 29(12):7674-7682.
View in:
PubMed
Breast Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022 06; 20(6):691-722.
View in:
PubMed
A look at current and potential treatment approaches for hormone receptor-positive, HER2-negative early breast cancer. Cancer. 2022 06 01; 128 Suppl 11:2209-2223.
View in:
PubMed
Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification. Ann Oncol. 2022 07; 33(7):702-712.
View in:
PubMed
Cardiac outcomes of subjects on adjuvant trastuzumab emtansine vs paclitaxel in combination with trastuzumab for stage I HER2-positive breast cancer (ATEMPT) study (TBCRC033): a randomized controlled trial. NPJ Breast Cancer. 2022 Feb 16; 8(1):18.
View in:
PubMed
Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03). J Clin Oncol. 2022 02 10; 40(5):449-458.
View in:
PubMed
Local Therapy Outcomes and Toxicity From the ATEMPT Trial (TBCRC 033): A Phase II Randomized Trial of Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab in Women With Stage I HER2-Positive Breast Cancer. Int J Radiat Oncol Biol Phys. 2022 05 01; 113(1):117-124.
View in:
PubMed
Should Ki-67 be adopted to select breast cancer patients for treatment with adjuvant abemaciclib? Ann Oncol. 2022 03; 33(3):234-238.
View in:
PubMed
Unmet challenges in systemic therapy for early stage breast cancer. Breast. 2022 Mar; 62 Suppl 1:S67-S69.
View in:
PubMed
Expanding Criteria for Prognostic Stage IA in Hormone Receptor-Positive Breast Cancer. J Natl Cancer Inst. 2021 11 29; 113(12):1744-1750.
View in:
PubMed
Prospective Study Testing a Simplified Paclitaxel Premedication Regimen in Patients with Early Breast Cancer. Oncologist. 2021 11; 26(11):927-933.
View in:
PubMed
The Global Landscape of Treatment Standards for Breast Cancer. J Natl Cancer Inst. 2021 09 04; 113(9):1143-1155.
View in:
PubMed
Continuous versus intermittent extended adjuvant letrozole for breast cancer: final results of randomized phase III SOLE (Study of Letrozole Extension) and SOLE Estrogen Substudy. Ann Oncol. 2021 10; 32(10):1256-1266.
View in:
PubMed
Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update. J Clin Oncol. 2021 12 10; 39(35):3959-3977.
View in:
PubMed
Customizing local and systemic therapies for women with early breast cancer: the St. Gallen International Consensus Guidelines for treatment of early breast cancer 2021. Ann Oncol. 2021 10; 32(10):1216-1235.
View in:
PubMed
Chemotherapy-related amenorrhea (CRA) after adjuvant ado-trastuzumab emtansine (T-DM1) compared to paclitaxel in combination with trastuzumab (TH) (TBCRC033: ATEMPT Trial). Breast Cancer Res Treat. 2021 Aug; 189(1):103-110.
View in:
PubMed
Adjuvant Trastuzumab Emtansine Versus Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT): A Randomized Clinical Trial. J Clin Oncol. 2021 07 20; 39(21):2375-2385.
View in:
PubMed
NCCN Guidelines® Insights: Breast Cancer, Version 4.2021. J Natl Compr Canc Netw. 2021 05 01; 19(5):484-493.
View in:
PubMed
NCCN Guidelines® Insights: Breast Cancer, Version 4.2021. J Natl Compr Canc Netw. 2021 05 01; 19(5):484-493.
View in:
PubMed
Physical Activity, Weight, and Outcomes in Patients Receiving Chemotherapy for Metastatic Breast Cancer (C40502/Alliance). JNCI Cancer Spectr. 2021 06; 5(3).
View in:
PubMed
Serial Analysis of Circulating Tumor Cells in Metastatic Breast Cancer Receiving First-Line Chemotherapy. J Natl Cancer Inst. 2021 04 06; 113(4):443-452.
View in:
PubMed
Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer. Reply. N Engl J Med. 2021 03 25; 384(12):1176-1177.
View in:
PubMed
Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study. Lancet Oncol. 2021 02; 22(2):212-222.
View in:
PubMed
Adjuvant Capecitabine in Triple-Negative Breast Cancer: New Strategies for Tailoring Treatment Recommendations. JAMA. 2021 01 05; 325(1):36-38.
View in:
PubMed
Systemic Therapy for Estrogen Receptor-Positive, HER2-Negative Breast Cancer. N Engl J Med. 2020 12 24; 383(26):2557-2570.
View in:
PubMed
A dynamic portrait of adverse events for breast cancer patients: results from a phase II clinical trial of eribulin in advanced HER2-negative breast cancer. Breast Cancer Res Treat. 2021 Jan; 185(1):135-144.
View in:
PubMed
Multidisciplinary considerations in the treatment of triple-negative breast cancer. CA Cancer J Clin. 2020 11; 70(6):432-442.
View in:
PubMed
Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. the COVID-19 pandemic breast cancer consortium. Breast Cancer Res Treat. 2020 Jun; 181(3):487-497.
View in:
PubMed
Avoiding Peg-Filgrastim Prophylaxis During the Paclitaxel Portion of the Dose-Dense Doxorubicin-Cyclophosphamide and Paclitaxel Regimen: A Prospective Study. J Clin Oncol. 2020 07 20; 38(21):2390-2397.
View in:
PubMed
Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy. Breast Cancer Res Treat. 2020 Jun; 181(2):347-359.
View in:
PubMed
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2020 04; 18(4):452-478.
View in:
PubMed
The legacy of Professor Aron Goldhirsch. Ann Oncol. 2020 06; 31(6):671-673.
View in:
PubMed
Neoadjuvant treatment strategies for HER2-positive breast cancer: cost-effectiveness and quality of life outcomes. Breast Cancer Res Treat. 2020 May; 181(1):43-51.
View in:
PubMed
Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol. 2019 Oct; 30(10):1541-1557.
View in:
PubMed
A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma. Ann Oncol. 2019 Sep; 30(9):1514-1520.
View in:
PubMed
Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer. Ann Oncol. 2012 Jan; 23(1):93-97.
View in:
PubMed
Corrections to "De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017". Ann Oncol. 2019 Jul; 30(7):1181.
View in:
PubMed
Adjuvant endocrine therapy in postmenopausal women: making treatment choices based on the magnitude of benefit. Breast. 2019 Nov; 48 Suppl 1:S89-S91.
View in:
PubMed
Estimating the benefits of therapy for early-stage breast cancer: the St. Gallen International Consensus Guidelines for the primary therapy of early breast cancer 2019. Ann Oncol. 2019 10 01; 30(10):1541-1557.
View in:
PubMed
A phase II feasibility study of palbociclib in combination with adjuvant endocrine therapy for hormone receptor-positive invasive breast carcinoma. Ann Oncol. 2019 09 01; 30(9):1514-1520.
View in:
PubMed
Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial. J Clin Oncol. 2019 09 10; 37(26):2338-2348.
View in:
PubMed
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2019 07 01; 30(7):1181.
View in:
PubMed
Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer. Ann Oncol. 2019 06 01; 30(6):1019.
View in:
PubMed
Molecular Testing in Breast Cancer. Am Soc Clin Oncol Educ Book. 2019 Jan; 39:e1-e7.
View in:
PubMed
Local-regional recurrence in women with small node-negative, HER2-positive breast cancer: results from a prospective multi-institutional study (the APT trial). Breast Cancer Res Treat. 2019 Jul; 176(2):303-310.
View in:
PubMed
Seven-Year Follow-Up Analysis of Adjuvant Paclitaxel and Trastuzumab Trial for Node-Negative, Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer. J Clin Oncol. 2019 08 01; 37(22):1868-1875.
View in:
PubMed
NCCN Guidelines Insights: Breast Cancer, Version 3.2018. J Natl Compr Canc Netw. 2019 02; 17(2):118-126.
View in:
PubMed
A Breath-Taking Diagnosis. N Engl J Med. 2019 01 03; 380(1):81-87.
View in:
PubMed
Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. J Oncol Pract. 2019 Feb; 15(2):106-107.
View in:
PubMed
Duration of adjuvant trastuzumab: might less be more? Ann Oncol. 2018 12 01; 29(12):2273-2274.
View in:
PubMed
Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update. J Clin Oncol. 2019 02 10; 37(5):423-438.
View in:
PubMed
Information Transparency in the Drug Approval Process. JAMA Oncol. 2018 11 01; 4(11):1621-1622.
View in:
PubMed
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2018 Oct 01; 29(10):2153.
View in:
PubMed
Functional Decline and Resilience in Older Women Receiving Adjuvant Chemotherapy for Breast Cancer. J Am Geriatr Soc. 2019 05; 67(5):920-927.
View in:
PubMed
Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer. N Engl J Med. 2018 Jul 12; 379(2):122-137.
View in:
PubMed
How Old is Too Old? Breast Cancer Treatment in Octogenarians. Ann Surg Oncol. 2018 06; 25(6):1458-1460.
View in:
PubMed
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018 Mar; 16(3):310-320.
View in:
PubMed
Clinical Cancer Advances 2018: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2018 04 01; 36(10):1020-1044.
View in:
PubMed
Reply to 'The St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2017: the point of view of an International Panel of Experts in Radiation Oncology' by Kirova et al. Ann Oncol. 2018 01 01; 29(1):281-282.
View in:
PubMed
Extended adjuvant intermittent letrozole versus continuous letrozole in postmenopausal women with breast cancer (SOLE): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2018 01; 19(1):127-138.
View in:
PubMed
De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017. Ann Oncol. 2017 08 01; 28(8):1700-1712.
View in:
PubMed
Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials. J Clin Oncol. 2017 Sep 20; 35(27):3113-3122.
View in:
PubMed
Blocking the Cycle: Cyclin-Dependent Kinase 4/6 Inhibitors in Metastatic, Hormone Receptor-Positive Breast Cancer. J Clin Oncol. 2017 Sep 01; 35(25):2866-2870.
View in:
PubMed
NCCN Guidelines Insights: Breast Cancer, Version 1.2017. J Natl Compr Canc Netw. 2017 04; 15(4):433-451.
View in:
PubMed
Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology. J Clin Oncol. 2017 04 20; 35(12):1341-1367.
View in:
PubMed
Experts' perspectives on the role of medical marijuana in oncology: A semistructured interview study. Psychooncology. 2017 08; 26(8):1087-1092.
View in:
PubMed
Biosimilar Therapy for ERBB2 (HER2)-Positive Breast Cancer: Close Enough? JAMA. 2017 01 03; 317(1):30-32.
View in:
PubMed
Optimizing Adjuvant Chemotherapy and Surgery for Early- and Late-Stage Breast Cancer. JAMA Oncol. 2016 Nov 01; 2(11):1399-1400.
View in:
PubMed
Breast conservation following neoadjuvant therapy for breast cancer in the modern era: Are we losing the opportunity? Eur J Surg Oncol. 2016 Dec; 42(12):1780-1786.
View in:
PubMed
Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance). Breast Cancer Res Treat. 2016 11; 160(2):297-304.
View in:
PubMed
Chemotherapy for Triple-Negative Breast Cancer: Is More Better? J Clin Oncol. 2016 10 01; 34(28):3369-71.
View in:
PubMed
Treatment of early-stage human epidermal growth factor 2-positive cancers among medicare enrollees: age and race strongly associated with non-use of trastuzumab. Breast Cancer Res Treat. 2016 08; 159(1):151-62.
View in:
PubMed
Endocrine Therapy for Hormone Receptor Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline Summary. J Oncol Pract. 2016 Jun; 12(6):583-7.
View in:
PubMed
Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline. J Clin Oncol. 2016 09 01; 34(25):3069-103.
View in:
PubMed
Update in Hematology and Oncology: Evidence Published in 2015. Ann Intern Med. 2016 May 03; 164(9):W32-6.
View in:
PubMed
Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial. J Clin Oncol. 2016 05 10; 34(14):1601-10.
View in:
PubMed
Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression Summary. J Oncol Pract. 2016 Apr; 12(4):390-3.
View in:
PubMed
Invasive Breast Cancer Version 1.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016 Mar; 14(3):324-54.
View in:
PubMed
Adjuvant Endocrine Therapy for Women With Hormone Receptor-Positive Breast Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update on Ovarian Suppression. J Clin Oncol. 2016 05 10; 34(14):1689-701.
View in:
PubMed
Cardiac Outcomes of Patients Receiving Adjuvant Weekly Paclitaxel and Trastuzumab for Node-Negative, ERBB2-Positive Breast Cancer. JAMA Oncol. 2016 Jan; 2(1):29-36.
View in:
PubMed
NCCN Guidelines Insights Breast Cancer, Version 1.2016. J Natl Compr Canc Netw. 2015 Dec; 13(12):1475-85.
View in:
PubMed
With better adjuvant therapy, does breast cancer stage still matter? BMJ. 2015 Oct 06; 351:h5273.
View in:
PubMed
Adjuvant endocrine therapy for postmenopausal women: Type and duration. Breast. 2015 Nov; 24 Suppl 2:S126-8.
View in:
PubMed
Postmenopausal breast cancer: a best endocrine strategy? Lancet. 2015 Oct 03; 386(10001):1317-1319.
View in:
PubMed
Nodal Irradiation after Breast-Cancer Surgery in the Era of Effective Adjuvant Therapy. N Engl J Med. 2015 Jul 23; 373(4):379-81.
View in:
PubMed
Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. Lancet Oncol. 2015 Jul; 16(7):848-58.
View in:
PubMed
Chemotherapy-related amenorrhea after adjuvant paclitaxel-trastuzumab (APT trial). Breast Cancer Res Treat. 2015 Jun; 151(3):589-96.
View in:
PubMed
Choosing Treatments on the Basis of Cost: Can Clinicians Opt for Less Expensive Treatments? J Oncol Pract. 2015 Jul; 11(4):322-4.
View in:
PubMed
Breast Cancer Version 2.2015. J Natl Compr Canc Netw. 2015 Apr; 13(4):448-75.
View in:
PubMed
Clinical cancer advances 2015: Annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol. 2015 Mar 01; 33(7):786-809.
View in:
PubMed
Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med. 2015 Jan 08; 372(2):134-41.
View in:
PubMed
Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med. 2015 Jan 29; 372(5):436-46.
View in:
PubMed
Endocrine therapy with or without inhibition of epidermal growth factor receptor and human epidermal growth factor receptor 2: a randomized, double-blind, placebo-controlled phase III trial of fulvestrant with or without lapatinib for postmenopausal women with hormone receptor-positive advanced breast cancer-CALGB 40302 (Alliance). J Clin Oncol. 2014 Dec 10; 32(35):3959-66.
View in:
PubMed
Long-term follow-up after preoperative trastuzumab and chemotherapy for HER2-overexpressing breast cancer. Clin Breast Cancer. 2015 Feb; 15(1):24-30.
View in:
PubMed
Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Joint analysis of IBCSG TEXT and SOFT trials. J Clin Oncol. 2014 Jun 20; 32(18_suppl):LBA1.
View in:
PubMed
Comparison of doxorubicin and cyclophosphamide versus single-agent paclitaxel as adjuvant therapy for breast cancer in women with 0 to 3 positive axillary nodes: CALGB 40101 (Alliance). J Clin Oncol. 2014 Aug 01; 32(22):2311-7.
View in:
PubMed
Outcomes by tumor subtype and treatment pattern in women with small, node-negative breast cancer: a multi-institutional study. J Clin Oncol. 2014 Jul 10; 32(20):2142-50.
View in:
PubMed
Past, present, and future challenges in breast cancer treatment. J Clin Oncol. 2014 Jul 01; 32(19):1979-86.
View in:
PubMed
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014 Jul 10; 371(2):107-18.
View in:
PubMed
Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: american society of clinical oncology clinical practice guideline focused update. J Clin Oncol. 2014 Jul 20; 32(21):2255-69.
View in:
PubMed
Breast cancer version 3.2014. J Natl Compr Canc Netw. 2014 Apr; 12(4):542-90.
View in:
PubMed
Sentinel lymph node biopsy for patients with early-stage breast cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2014 May 01; 32(13):1365-83.
View in:
PubMed
Neoadjuvant pertuzumab: the exception that proves the rule? Oncology (Williston Park). 2014 Mar; 28(3):197-9.
View in:
PubMed
Fifty years of systemic therapy for breast cancer: from one size fits all to tailored therapy. Am Soc Clin Oncol Educ Book. 2014; e1-3.
View in:
PubMed
Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy. J Natl Compr Canc Netw. 2014 Jan; 12(1):71-80.
View in:
PubMed
Trastuzumab: qui bono? J Natl Cancer Inst. 2013 Dec 04; 105(23):1772-5.
View in:
PubMed
Personalized medicine in breast cancer: tamoxifen, endoxifen, and CYP2D6 in clinical practice. Breast Cancer Res Treat. 2013 Oct; 141(3):421-7.
View in:
PubMed
Patients with triple negative breast cancer: is there an optimal adjuvant treatment? Breast. 2013 Aug; 22 Suppl 2:S147-8.
View in:
PubMed
Clinicopathological features among patients with advanced human epidermal growth factor-2-positive breast cancer with prolonged clinical benefit to first-line trastuzumab-based therapy: a retrospective cohort study. Clin Breast Cancer. 2013 Aug; 13(4):254-63.
View in:
PubMed
Lucky to be an oncologist. J Natl Compr Canc Netw. 2013 Aug; 11(8):909-10.
View in:
PubMed
Expert opinion vs guideline based care: the St. Gallen Case study. Breast. 2013 Aug; 22 Suppl 2:S1-2.
View in:
PubMed
Breast cancer, version 3.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2013 Jul; 11(7):753-60; quiz 761.
View in:
PubMed
Breast cancer treatment in the era of individualized care. Hematol Oncol Clin North Am. 2013 Aug; 27(4):xiii-xv.
View in:
PubMed
Lou Gehrig, Angelina Jolie, and cancer genetics. J Natl Compr Canc Netw. 2013 Jun 01; 11(6):631-2.
View in:
PubMed
A phase II study of bevacizumab in combination with vinorelbine and trastuzumab in HER2-positive metastatic breast cancer. Breast Cancer Res Treat. 2013 Jun; 139(2):403-10.
View in:
PubMed
Off-label use of oncology drugs: too much, too little, or just right? J Natl Compr Canc Netw. 2013 May 01; 11(5):505-6.
View in:
PubMed
Keeping cancer patients out of the hospital at the end of life. J Natl Compr Canc Netw. 2013 Mar 01; 11(3):229-30.
View in:
PubMed
High performance teamwork training and systems redesign in outpatient oncology. BMJ Qual Saf. 2013 May; 22(5):405-13.
View in:
PubMed
Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era. Breast. 2013 Aug; 22(4):525-31.
View in:
PubMed
Caring for breast cancer survivors. J Natl Compr Canc Netw. 2013 Jan 01; 11(1):1-2.
View in:
PubMed
Implementation of team training in outpatient breast oncology. J Clin Oncol. 2012 Dec; 30(34_suppl):83.
View in:
PubMed
Measuring hope: patient expectations of chemotherapy for advanced cancer. J Natl Compr Canc Netw. 2012 Dec 01; 10(12):1459-60.
View in:
PubMed
A "shot heard 'round the world" on cancer drug costs? J Natl Compr Canc Netw. 2012 Nov 01; 10(11):1315-6.
View in:
PubMed
Should response to preoperative chemotherapy affect radiotherapy recommendations after mastectomy for stage II breast cancer? J Clin Oncol. 2012 Nov 10; 30(32):3916-20.
View in:
PubMed
Assuring access to academic cancer centers. J Natl Compr Canc Netw. 2012 Oct 01; 10(10):1177-8.
View in:
PubMed
Combination antiangiogenic therapy in advanced breast cancer: a phase 1 trial of vandetanib, a VEGFR inhibitor, and metronomic chemotherapy, with correlative platelet proteomics. Breast Cancer Res Treat. 2012 Nov; 136(1):169-78.
View in:
PubMed
Pathway-based oncology care: time for more transparency. J Natl Compr Canc Netw. 2012 Sep; 10(9):1043-4.
View in:
PubMed
Making genuine progress against metastatic breast cancer. J Clin Oncol. 2012 Oct 01; 30(28):3448-51.
View in:
PubMed
Adjuvant therapy in stage I carcinoma of the breast: the influence of multigene analyses and molecular phenotyping. Breast J. 2012 Jul-Aug; 18(4):303-11.
View in:
PubMed
Simplifying guidelines: we only need one adjuvant chemotherapy regimen for breast cancer. J Natl Compr Canc Netw. 2012 Jul 01; 10(7):797-8.
View in:
PubMed
Metastatic breast cancer, version 1.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw. 2012 Jul 01; 10(7):821-9.
View in:
PubMed
Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol. 2012 Jul 20; 30(21):2585-92.
View in:
PubMed
The top five in oncology: where do we go from here? J Natl Compr Canc Netw. 2012 Jun 01; 10(6):681-2.
View in:
PubMed
Estimation of tamoxifen metabolite concentrations in the blood of breast cancer patients through CYP2D6 genotype activity score. Breast Cancer Res Treat. 2012 Jun; 133(2):677-83.
View in:
PubMed
Choosing the best trastuzumab-based adjuvant chemotherapy regimen: should we abandon anthracyclines? J Clin Oncol. 2012 Jun 20; 30(18):2179-82.
View in:
PubMed
If the choices are all the same, why not prefer the less-expensive option? J Natl Compr Canc Netw. 2012 Apr; 10(4):425-6.
View in:
PubMed
Breast cancer: Neoadjuvant bevacizumab treatment-signal or noise? Nat Rev Clin Oncol. 2012 Mar 13; 9(4):191-2.
View in:
PubMed
Patient advocates' role in clinical trials: perspectives from Cancer and Leukemia Group B investigators and advocates. Cancer. 2012 Oct 01; 118(19):4801-5.
View in:
PubMed
Pre-judging data: benchmarking clinical significance before study results are known. J Natl Compr Canc Netw. 2012 Mar; 10(3):289-90.
View in:
PubMed
Disclosing pharma payments to oncologists: what will we learn? J Natl Compr Canc Netw. 2012 Feb; 10(2):133-4.
View in:
PubMed
Deep time: the long and the short of adjuvant endocrine therapy for breast cancer. J Clin Oncol. 2012 Mar 01; 30(7):684-6.
View in:
PubMed
Update of the oxford overview: new insight and perspectives in the era of personalized medicine. Am Soc Clin Oncol Educ Book. 2012; 71-9.
View in:
PubMed
JNCCN reaches 10. J Natl Compr Canc Netw. 2012 Jan; 10(1):3.
View in:
PubMed
Avastin for breast cancer, 2005-2011: requiescat in pacem? J Natl Compr Canc Netw. 2011 Dec; 9(12):1321-3.
View in:
PubMed
The continuity of care checklist: a critical frontier in patient safety. J Natl Compr Canc Netw. 2011 Nov; 9(11):1217-8.
View in:
PubMed
Can axillary node dissection be omitted in a subset of patients with low local and regional failure rates? Breast J. 2012 Jan-Feb; 18(1):23-7.
View in:
PubMed
Patients with anti-HER2 responsive disease: definition and adjuvant therapies. Breast. 2011 Oct; 20 Suppl 3:S132-4.
View in:
PubMed
Have we been down this road before? J Natl Compr Canc Netw. 2011 Sep 01; 9(9):953.
View in:
PubMed
Peek before you treat? Is it a fantasy or reality? J Oncol Pract. 2011 Sep; 7(5):338-9.
View in:
PubMed
American Society of Clinical Oncology clinical practice guideline update on the use of chemotherapy sensitivity and resistance assays. J Clin Oncol. 2011 Aug 20; 29(24):3328-30.
View in:
PubMed
The fifth "C" is cost: highlights from ASCO 2011. J Natl Compr Canc Netw. 2011 Jul 01; 9(7):691.
View in:
PubMed
Radiation therapy for ductal carcinoma in situ: a decision analysis. Cancer. 2012 Feb 01; 118(3):603-11.
View in:
PubMed
Surgery of the primary tumor does not improve survival in stage IV breast cancer. Breast Cancer Res Treat. 2011 Sep; 129(2):459-65.
View in:
PubMed
CMF revisited in the 21st century. Ann Oncol. 2012 Feb; 23(2):305-11.
View in:
PubMed
Introduction: Current and future approaches to chemotherapy in patients with resistant breast cancer. Semin Oncol. 2011 Jun; 38 Suppl 2:S1-2.
View in:
PubMed
Novel agents and future directions for refractory breast cancer. Semin Oncol. 2011 Jun; 38 Suppl 2:S17-24.
View in:
PubMed
Long-term outcomes after neoadjuvant trastuzumab and chemotherapy for HER2+ breast cancer. J Clin Oncol. 2011 May 20; 29(15_suppl):e11074.
View in:
PubMed
Recent advances in the treatment of breast cancer: highlights from the 2010 San Antonio Breast Cancer Symposium. Clin Adv Hematol Oncol. 2011 May; 9(5 Suppl 11):1-16.
View in:
PubMed
Texting the doctor. J Natl Compr Canc Netw. 2011 May; 9(5):459.
View in:
PubMed
Responses to subsequent anti-HER2 therapy after treatment with trastuzumab-DM1 in women with HER2-positive metastatic breast cancer. Ann Oncol. 2012 Jan; 23(1):93-97.
View in:
PubMed
Contrary effects of the receptor tyrosine kinase inhibitor vandetanib on constitutive and flow-stimulated nitric oxide elaboration in humans. Hypertension. 2011 Jul; 58(1):85-92.
View in:
PubMed
Mind the gap. J Natl Compr Canc Netw. 2011 Apr; 9(4):343.
View in:
PubMed
Impact of lapatinib plus trastuzumab versus single-agent lapatinib on quality of life of patients with trastuzumab-refractory HER2+ metastatic breast cancer. Ann Oncol. 2011 Dec; 22(12):2582-2590.
View in:
PubMed
Bevacizumab for advanced breast cancer: all tied up with a RIBBON? J Clin Oncol. 2011 Apr 01; 29(10):1232-5.
View in:
PubMed
EMBRACE, eribulin, and new realities of advanced breast cancer. Lancet. 2011 Mar 12; 377(9769):878-80.
View in:
PubMed
Zoledronic acid preserves bone mineral density in premenopausal women who develop ovarian failure due to adjuvant chemotherapy: final results from CALGB trial 79809. Eur J Cancer. 2011 Mar; 47(5):683-9.
View in:
PubMed
Take your medicine. J Natl Compr Canc Netw. 2011 Feb; 9 Suppl 3:S1.
View in:
PubMed
Invasive breast cancer. J Natl Compr Canc Netw. 2011 Feb; 9(2):136-222.
View in:
PubMed
Take Your Medicine J Natl Compr Canc Netw. 2011 Feb 01; 9(9 Suppl 3):S1.
View in:
PubMed
Congestive heart failure risk in patients with breast cancer treated with bevacizumab. J Clin Oncol. 2011 Feb 20; 29(6):632-8.
View in:
PubMed
Beaten at the Alamo by the Europeans. J Natl Compr Canc Netw. 2011 Jan; 9(1):1.
View in:
PubMed
Board recertification. J Natl Compr Canc Netw. 2010 Oct; 8(10):1111.
View in:
PubMed
Breast cancer: noninvasive and special situations. J Natl Compr Canc Netw. 2010 Oct; 8(10):1182-207.
View in:
PubMed
Cardiac toxicity from systemic cancer therapy: a comprehensive review. Prog Cardiovasc Dis. 2010 Sep-Oct; 53(2):94-104.
View in:
PubMed
Addressing oncology pharmacy & policy. J Natl Compr Canc Netw. 2010 Sep; 8 Suppl 7:S1.
View in:
PubMed
American society of clinical oncology clinical practice guideline update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Oncol Pract. 2010 Sep; 6(5):243-6.
View in:
PubMed
Avastin, ODAC, and the FDA: are we drafting the right players? J Natl Compr Canc Netw. 2010 Aug; 8(8):833-4.
View in:
PubMed
American Society of Clinical Oncology clinical practice guideline: update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Clin Oncol. 2010 Aug 10; 28(23):3784-96.
View in:
PubMed
Adjuvant hormonal therapy for early-stage breast cancer. Surg Oncol Clin N Am. 2010 Jul; 19(3):639-47.
View in:
PubMed
SABRE-B: an evaluation of paclitaxel and bevacizumab with or without sunitinib as first-line treatment of metastatic breast cancer. Ann Oncol. 2010 Dec; 21(12):2370-2376.
View in:
PubMed
Re-engineering the cooperative groups. J Natl Compr Canc Netw. 2010 May; 8(5):505.
View in:
PubMed
Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol. 2010 Mar 10; 28(8):1301-7.
View in:
PubMed
Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010 Mar 01; 28(7):1124-30.
View in:
PubMed
Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy. J Clin Oncol. 2009 Dec 01; 27(34):5671-3.
View in:
PubMed
Screening contretemps: the real issue in the mammogram guideline debate. J Natl Compr Canc Netw. 2009 Nov; 7(10):1039-40.
View in:
PubMed
Late effects of adjuvant systemic therapies in women diagnosed with breast cancer at a young age. Breast. 2009 Oct; 18 Suppl 3:S135-6.
View in:
PubMed
What is a patient navigator, and should we have them in major cancer centers? J Natl Compr Canc Netw. 2009 Oct; 7(9):905.
View in:
PubMed
NCCN Task Force Report: Estrogen Receptor and Progesterone Receptor Testing in Breast Cancer by Immunohistochemistry. J Natl Compr Canc Netw. 2009 Sep; 7 Suppl 6:S1-S21; quiz S22-3.
View in:
PubMed
Colon cancer: the new breast cancer. J Natl Compr Canc Netw. 2009 Sep; 7(8):773.
View in:
PubMed
NCCN task force report: management of neuropathy in cancer. J Natl Compr Canc Netw. 2009 Sep; 7 Suppl 5:S1-S26; quiz S27-8.
View in:
PubMed
Case records of the Massachusetts General Hospital. Case 25-2009. A 36-year-old woman with hormone-receptor-positive breast cancer. N Engl J Med. 2009 Aug 13; 361(7):699-707.
View in:
PubMed
Cancer-related direct-to-consumer advertising: awareness, perceptions, and reported impact among patients undergoing active cancer treatment. J Clin Oncol. 2009 Sep 01; 27(25):4182-7.
View in:
PubMed
Third consensus on medical treatment of metastatic breast cancer. Ann Oncol. 2009 Nov; 20(11):1771-85.
View in:
PubMed
Quality measures, clinical practice, NCCN, and McAllen, Texas. J Natl Compr Canc Netw. 2009 Jul; 7(7):695.
View in:
PubMed
Personalizing treatment in early-stage breast cancer: The role of standard clinical factors and genomic information in adjuvant chemotherapy decision making. J Clin Oncol. 2009 May 20; 27(15_suppl):572.
View in:
PubMed
Adjuvant chemotherapy in older women with early-stage breast cancer. N Engl J Med. 2009 May 14; 360(20):2055-65.
View in:
PubMed
Do clinical trials belong in clinical guidelines? J Natl Compr Canc Netw. 2009 May; 7(5):489.
View in:
PubMed
By the way, doctor. I've been having PET-CT scans to look for any growth or spread of previously removed tumors. Are they as reliable in detecting breast cancer as a regular mammogram? Harv Health Lett. 2009 May; 34(7):2.
View in:
PubMed
SPIKES for difficult conversations with cancer patients. J Natl Compr Canc Netw. 2009 Apr; 7(4):341.
View in:
PubMed
Tolerability of and adherence to combination oral therapy with gefitinib and capecitabine in metastatic breast cancer. Breast Cancer Res Treat. 2009 Oct; 117(3):615-23.
View in:
PubMed
Breast cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2009 Feb; 7(2):122-92.
View in:
PubMed
Personalized medicine and breast cancer care. J Natl Compr Canc Netw. 2009 Feb; 7(2):109.
View in:
PubMed
Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens. Ann Oncol. 2009 Jun; 20(6):1026-31.
View in:
PubMed
Circulating tumor cells in HER-2 positive metastatic breast cancer patients treated with trastuzumab and chemotherapy. Int J Biol Markers. 2009 Jan-Mar; 24(1):1-10.
View in:
PubMed
AAV2/1-TNFR:Fc gene delivery prevents periodontal disease progression. Gene Ther. 2009 Mar; 16(3):426-36.
View in:
PubMed
Updates in anti-HER2 combination therapy. Clin Adv Hematol Oncol. 2008 Dec; 6(12):873-4.
View in:
PubMed
VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res. 2008 Dec 01; 14(23):7871-7.
View in:
PubMed
Self-reported practices and attitudes of US oncologists regarding off-protocol therapy. J Clin Oncol. 2008 Dec 20; 26(36):5994-6000.
View in:
PubMed
Improving tolerance of AIs: predicting risk and uncovering mechanisms of musculoskeletal toxicity. Oncology (Williston Park). 2008 Nov 15; 22(12):1416, 1424.
View in:
PubMed
Conflict of interest and oncology guidelines. J Natl Compr Canc Netw. 2008 Nov; 6(10):955.
View in:
PubMed
Oncology teamwork. J Natl Compr Canc Netw. 2008 Sep; 6(8):715.
View in:
PubMed
NCCN Task Force Report: mTOR inhibition in solid tumors. J Natl Compr Canc Netw. 2008 Sep; 6 Suppl 5:S1-20; quiz S21-2.
View in:
PubMed
Lymphopenia associated with adjuvant anthracycline/ taxane regimens. Clin Breast Cancer. 2008 Aug; 8(4):352-6.
View in:
PubMed
Breast surgery in stage IV breast cancer: impact of staging and patient selection on overall survival. Breast Cancer Res Treat. 2009 May; 115(1):7-12.
View in:
PubMed
A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. J Clin Oncol. 2008 May 20; 26(15_suppl):1015.
View in:
PubMed
A pilot study of adjuvant bevacizumab and chemotherapy after neoadjuvant chemotherapy for high-risk breast cancer. J Clin Oncol. 2008 May 20; 26(15_suppl):519.
View in:
PubMed
Cancer-related direct-to-consumer advertising: awareness, perceived impact, and associated patient and provider behavior. J Clin Oncol. 2008 May 20; 26(15_suppl):6631.
View in:
PubMed
Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: a modeling analysis. J Natl Cancer Inst. 2008 May 07; 100(9):642-8.
View in:
PubMed
Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2008 Apr 20; 26(12):1993-9.
View in:
PubMed
Preoperative therapy as a model for translational research in breast cancer. Cancer Invest. 2008 Apr-May; 26(3):217-21.
View in:
PubMed
Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol. 2008 Apr 01; 26(10):1642-9.
View in:
PubMed
Phase II study of sunitinib malate, an oral multitargeted tyrosine kinase inhibitor, in patients with metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol. 2008 Apr 10; 26(11):1810-6.
View in:
PubMed
Weighing a dose-dense option for adjuvant chemotherapy and trastuzumab in early-stage breast cancer. J Clin Oncol. 2008 Mar 10; 26(8):1198-200.
View in:
PubMed
A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol. 2008 Jun; 19(6):1068-74.
View in:
PubMed
Preoperative therapy in invasive breast cancer: pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol. 2008 Feb 10; 26(5):814-9.
View in:
PubMed
Molecular origins of cancer. N Engl J Med. 2008 Jan 31; 358(5):527.
View in:
PubMed
NCCN Task Force Report: breast cancer in the older woman. J Natl Compr Canc Netw. 2008; 6 Suppl 4:S1-25; quiz S26-7.
View in:
PubMed
Aromatase inhibitors and arthralgias: a new frontier in symptom management for breast cancer survivors. J Clin Oncol. 2007 Sep 01; 25(25):3797-9.
View in:
PubMed
Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer. 2007 Sep 01; 110(5):965-72.
View in:
PubMed
Cognitive side-effects of adjuvant treatments. Breast. 2007 Dec; 16 Suppl 2:S166-8.
View in:
PubMed
NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer. J Natl Compr Canc Netw. 2007 May; 5 Suppl 1:S1-22; quiz S23-2.
View in:
PubMed
Biological basis of breast cancer: an introduction. Semin Oncol. 2007 Apr; 34(2 Suppl 3):S1-3.
View in:
PubMed
Chemotherapy for metastatic breast cancer. Hematol Oncol Clin North Am. 2007 Apr; 21(2):257-72.
View in:
PubMed
Anemia in cancer: update on studies of erythropoiesis-stimulating agents. J Support Oncol. 2007 Apr; 5(4 Suppl 2):5-26.
View in:
PubMed
Aromatase inhibitor-associated arthralgia syndrome. Breast. 2007 Jun; 16(3):223-34.
View in:
PubMed
Phase II study of CT-2103 as first- or second-line chemotherapy in patients with metastatic breast cancer: unexpected incidence of hypersensitivity reactions. Invest New Drugs. 2007 Aug; 25(4):369-75.
View in:
PubMed
Invasive breast cancer. J Natl Compr Canc Netw. 2007 Mar; 5(3):246-312.
View in:
PubMed
Novel approaches to advanced breast cancer: bevacizumab and lapatinib. J Natl Compr Canc Netw. 2007 Mar; 5(3):314-23.
View in:
PubMed
Predictors of resistance to preoperative trastuzumab and vinorelbine for HER2-positive early breast cancer. Clin Cancer Res. 2007 Feb 15; 13(4):1198-207.
View in:
PubMed
Clinical trial update: implications and management of residual disease after neoadjuvant therapy for breast cancer. Breast Cancer Res. 2007; 9(5):110.
View in:
PubMed
Myeloid growth factor support for dose-dense adjuvant chemotherapy for breast cancer. Oncology (Williston Park). 2006 Dec; 20(14 Suppl 9):13-5.
View in:
PubMed
Pneumocystis carinii pneumonia during dose-dense chemotherapy for breast cancer. J Clin Oncol. 2006 Nov 20; 24(33):5330-1.
View in:
PubMed
The role of angiogenesis inhibition in the treatment of breast cancer. Clin Adv Hematol Oncol. 2006 Oct; 4(10 Suppl 21):1-10; quiz 11-2.
View in:
PubMed
Rebeccamycin analog for refractory breast cancer: a randomized phase II trial of dosing schedules. Invest New Drugs. 2007 Apr; 25(2):161-4.
View in:
PubMed
Second consensus on medical treatment of metastatic breast cancer. Ann Oncol. 2007 Feb; 18(2):215-25.
View in:
PubMed
HER2 testing in breast cancer: NCCN Task Force report and recommendations. J Natl Compr Canc Netw. 2006 Jul; 4 Suppl 3:S1-22; quiz S23-4.
View in:
PubMed
Effect of treatment with sunitinib malate, a multitargeted tyrosine kinase inhibitor, on circulating plasma levels of VEGF, soluble VEGF receptors 2 and 3, and soluble KIT in patients with metastatic breast cancer. J Clin Oncol. 2006 Jun 20; 24(18_suppl):578.
View in:
PubMed
Combination therapy with gefitinib and capecitabine in metastatic breast cancer (MBC): A phase I trial. J Clin Oncol. 2006 Jun 20; 24(18_suppl):10564.
View in:
PubMed
Use of experimental therapy outside of clinical trials among U.S. oncologists. J Clin Oncol. 2006 Jun 20; 24(18_suppl):6047.
View in:
PubMed
Trastuzumab and vinorelbine or taxane chemotherapy for HER2+ metastatic breast cancer: The TRAVIOTA study. J Clin Oncol. 2006 Jun 20; 24(18_suppl):650.
View in:
PubMed
The impact of tumor progesterone receptor status on optimal adjuvant endocrine therapy for postmenopausal patients with early-stage breast cancer: a decision analysis. Cancer. 2006 Jun 15; 106(12):2576-82.
View in:
PubMed
Inadvertent use of aromatase inhibitors in patients with breast cancer with residual ovarian function: cases and lessons. Clin Breast Cancer. 2006 Jun; 7(2):158-61.
View in:
PubMed
NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. J Natl Compr Canc Netw. 2006 Mar; 4 Suppl 1:S1-26.
View in:
PubMed
Standards for follow-up care of patents with breast cancer. Breast. 2005 Dec; 14(6):500-8.
View in:
PubMed
Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol. 2005 Nov 20; 23(33):8340-7.
View in:
PubMed
Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer. Int J Radiat Oncol Biol Phys. 2006 Feb 01; 64(2):496-504.
View in:
PubMed
The distinctive nature of HER2-positive breast cancers. N Engl J Med. 2005 Oct 20; 353(16):1652-4.
View in:
PubMed
American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005 Oct 20; 23(30):7703-20.
View in:
PubMed
Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy. Ann Oncol. 2005 Nov; 16(11):1772-7.
View in:
PubMed
Highlights of the American Society of Clinical Oncology annual meeting 2005. 13-17 May, 2005, Florida, USA. Expert Rev Anticancer Ther. 2005 Aug; 5(4):581-3.
View in:
PubMed
Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis. J Clin Oncol. 2005 Aug 01; 23(22):5178-87.
View in:
PubMed
Phase II study of SU11248, a multitargeted receptor tyrosine kinase inhibitor (TKI), in patients (pts) with previously treated metastatic breast cancer (MBC). J Clin Oncol. 2005 Jun; 23(16_suppl):563.
View in:
PubMed
Optimizing endocrine therapy in postmenopausal women with early stage breast cancer: A decision analysis for biological subsets of tumors. J Clin Oncol. 2005 Jun; 23(16_suppl):529.
View in:
PubMed
Breast cancer. J Natl Compr Canc Netw. 2005 May; 3(3):238-89.
View in:
PubMed
HER2 or not HER2: that is the question. J Clin Oncol. 2005 Jun 01; 23(16):3656-9.
View in:
PubMed
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol. 2005 Jan 20; 23(3):619-29.
View in:
PubMed
American Society of Clinical Oncology Technology Assessment: chemotherapy sensitivity and resistance assays. J Clin Oncol. 2004 Sep 01; 22(17):3631-8.
View in:
PubMed
Rebeccamycin analog for refractory breast cancer: a randomized phase II trial. J Clin Oncol. 2004 Jul 15; 22(14_suppl):547.
View in:
PubMed
Phase II, 3-arm study of CCI-779 in combination with letrozole in postmenopausal women with locally advanced or metastatic breast cancer: preliminary results. J Clin Oncol. 2004 Jul 15; 22(14_suppl):544.
View in:
PubMed
Ductal carcinoma in situ of the breast. N Engl J Med. 2004 Apr 01; 350(14):1430-41.
View in:
PubMed
Trastuzumab regimens for HER2-overexpressing metastatic breast cancer. Clin Breast Cancer. 2003 Dec; 4(5):329-37; discussion 338-9.
View in:
PubMed
Follow-up care of breast cancer survivors. Semin Oncol. 2003 Dec; 30(6):817-25.
View in:
PubMed
Beyond tamoxifen--extending endocrine treatment for early-stage breast cancer. N Engl J Med. 2003 Nov 06; 349(19):1857-9.
View in:
PubMed
Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol. 2003 Aug 01; 21(15):2889-95.
View in:
PubMed
Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer. 2003 Jun 15; 97(12):2972-7.
View in:
PubMed
Use of the peroxisome proliferator-activated receptor (PPAR) gamma ligand troglitazone as treatment for refractory breast cancer: a phase II study. Breast Cancer Res Treat. 2003 Jun; 79(3):391-7.
View in:
PubMed
American Society of Clinical Oncology technology assessment working group update: use of aromatase inhibitors in the adjuvant setting. J Clin Oncol. 2003 Jul 01; 21(13):2597-9.
View in:
PubMed
Quality of non-breast cancer health maintenance among elderly breast cancer survivors. J Clin Oncol. 2003 Apr 15; 21(8):1447-51.
View in:
PubMed
Do patients participating in clinical trials want to know study results? J Natl Cancer Inst. 2003 Mar 19; 95(6):491-2.
View in:
PubMed
Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol. 2003 Jan 01; 21(1):46-53.
View in:
PubMed
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for women with hormone receptor-positive breast cancer: status report 2002. J Clin Oncol. 2002 Aug 01; 20(15):3317-27.
View in:
PubMed
American Society of Clinical Oncology technology assessment of pharmacologic interventions for breast cancer risk reduction including tamoxifen, raloxifene, and aromatase inhibition. J Clin Oncol. 2002 Aug 01; 20(15):3328-43.
View in:
PubMed
Gemcitabine-induced radiation recall. Int J Radiat Oncol Biol Phys. 2002 Jun 01; 53(2):394-400.
View in:
PubMed
HER2 overexpressing metastatic breast cancer. Curr Treat Options Oncol. 2002 Apr; 3(2):163-74.
View in:
PubMed
Treatment of breast cancer during pregnancy. Expert Opin Pharmacother. 2002 Apr; 3(4):423-8.
View in:
PubMed
New cytotoxic agents and schedules for advanced breast cancer. Semin Oncol. 2001 Aug; 28(4):344-58.
View in:
PubMed
Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2001 May 15; 19(10):2722-30.
View in:
PubMed
Unusual aspects of breast cancer: case 2. Synchronous bilateral lung and breast cancers. J Clin Oncol. 2001 May 01; 19(9):2571-3.
View in:
PubMed
Side effects of chemotherapy and combined chemohormonal therapy in women with early-stage breast cancer. J Natl Cancer Inst Monogr. 2001; (30):135-42.
View in:
PubMed
New combinations with Herceptin in metastatic breast cancer. Oncology. 2001; 61 Suppl 2:50-7.
View in:
PubMed
Primary care for survivors of breast cancer. N Engl J Med. 2000 Oct 12; 343(15):1086-94.
View in:
PubMed
Discussing complementary therapies with cancer patients: what should we be talking about? J Clin Oncol. 2000 Jul; 18(13):2501-4.
View in:
PubMed
Docetaxel administered on a weekly basis for metastatic breast cancer. J Clin Oncol. 2000 Mar; 18(6):1212-9.
View in:
PubMed
Side effects of chemotherapy. Case 1. Radiation recall dermatitis from gemcitabine. J Clin Oncol. 2000 Feb; 18(3):693-4.
View in:
PubMed
Phase I study of Doxil and vinorelbine in metastatic breast cancer. Ann Oncol. 1999 Sep; 10(9):1113-6.
View in:
PubMed
Use of alternative medicine by women with early-stage breast cancer. N Engl J Med. 1999 Jun 03; 340(22):1733-9.
View in:
PubMed
Hypertrophic osteoarthropathy. J Clin Oncol. 1997 Jul; 15(7):2759-60.
View in:
PubMed
Identification of amino acid residues of the retroviral aspartic proteinases important for substrate specificity and catalytic efficiency. Adv Exp Med Biol. 1995; 362:399-406.
View in:
PubMed
Mutational analysis of the substrate binding pockets of the Rous sarcoma virus and human immunodeficiency virus-1 proteases. J Biol Chem. 1994 Apr 15; 269(15):11170-7.
View in:
PubMed
Determinants of helper T cell-dependent antibody production. Semin Immunol. 1993 Dec; 5(6):441-7.
View in:
PubMed
In vivo role of interleukin 4 in T cell tolerance induced by aqueous protein antigen. J Exp Med. 1993 Feb 01; 177(2):457-63.
View in:
PubMed
Proteolysis in the maturation of avian retroviruses does not require calcium. Virology. 1992 Aug; 189(2):771-4.
View in:
PubMed
Aqueous antigens induce in vivo tolerance selectively in IL-2- and IFN-gamma-producing (Th1) cells. J Immunol. 1992 Jun 15; 148(12):3687-91.
View in:
PubMed
Mutations that alter the activity of the Rous sarcoma virus protease. J Biol Chem. 1992 May 15; 267(14):9481-90.
View in:
PubMed
Analysis of substrate interactions of the Rous sarcoma virus wild type and mutant proteases and human immunodeficiency virus-1 protease using a set of systematically altered peptide substrates. J Biol Chem. 1992 May 15; 267(14):9491-8.
View in:
PubMed
Processing of avian retroviral gag polyprotein precursors is blocked by a mutation at the NC-PR cleavage site. J Virol. 1992 Mar; 66(3):1781-5.
View in:
PubMed
Assembly and processing of avian retroviral gag polyproteins containing linked protease dimers. J Virol. 1991 Nov; 65(11):6165-72.
View in:
PubMed
Humoral immune functions in IL-4 transgenic mice. J Immunol. 1991 Nov 01; 147(9):2950-6.
View in:
PubMed
Activation and functions of CD4+ T-cell subsets. Immunol Rev. 1991 Oct; 123:5-22.
View in:
PubMed
T-cell-mediated activation of B cells. Curr Opin Immunol. 1991 Jun; 3(3):345-9.
View in:
PubMed
Functional phospholipid/sphingomyelin ratio: an easy to interpret indicator of fetal lung maturity. Ann Clin Lab Sci. 1986 Sep-Oct; 16(5):407-11.
View in:
PubMed
Degree of unsaturation of the fatty acid chains of phospholipids influences the fluorescence polarization: implications for evaluating fetal lung maturity. Clin Chem. 1986 Mar; 32(3):425-8.
View in:
PubMed
MAMMARY PAGET'S DISEASE. Skin (Los Angeles). 1964 Jul; 3:206-11.
View in:
PubMed